Back to Catalog
CellCentric
cellcentric
Clinical-stage biotech developing inobrodib, an oral p300/CBP inhibitor for multiple myeloma.
Total Funding
$424M
sector:biotech
stage:series_c_plus
oncology
clinical-stage
precision-medicine
Full Profile Gated
Register as a Qualified Purchaser to access the full profile of CellCentric, including financial analysis, competitive landscape, and investment thesis.